MedTrace Logo

CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.

NCT03381326 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2023-06-02

No results posted yet for this study

Summary

Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.

Conditions

Interventions

PROCEDURE

blood and FFPE sample collection

blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection

Sponsors & Collaborators

  • Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

    lead OTHER

Principal Investigators

  • Ugo De Giorgi · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-15
Primary Completion
2019-10-31
Completion
2023-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03381326 on ClinicalTrials.gov